Give me the fringe/less validated options about how can I monitor progression from marginal zone to dlbcl? How might...
According to the NCCN Guidelines (2023), the standard monitoring typically involves regular clinical exams and imaging. However, there are some emerging and less validated approaches being studied:
Potential Monitoring Methods (Less Validated):
- According to the Leukemia & Lymphoma Society's latest research updates:
- Liquid biopsy/circulating tumor DNA testing may help detect transformation earlier, though this is still investigational
- Molecular markers like MYC or BCL2 rearrangements might indicate higher transformation risk
- PET-CT SUV changes over time may help predict transformation risk
Risk Factors for Progression: The NCCN Guidelines and Lymphoma Research Foundation identify several factors that may increase transformation risk:
- Higher-risk features:
- Elevated LDH levels
- B symptoms (fever, night sweats, weight loss)
- Multiple sites of involvement
- Advanced stage disease
- Molecular features (less validated but studied):
- Certain genetic mutations (p53, MYD88)
- Specific chromosomal abnormalities
Important Caveats:
- The Leukemia & Lymphoma Society emphasizes that transformation risk varies significantly between individuals and is often unpredictable
- NCCN Guidelines stress that these risk factors are not definitive predictors
Always discuss monitoring plans with your healthcare team, as they can best determine the appropriate surveillance strategy based on your specific situation. These less validated options should be considered supplementary to standard monitoring approaches.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients (Lymphomas) — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Question asked:
Give me the fringe/less validated options about how can I monitor progression from marginal zone to dlbcl? How might I predict my likelihood to progress - any factors?
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients (Lymphomas) (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with prognosis for Lymphoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
Expert Webinars on Lymphoma
More questions about Lymphoma
- How often should I get scans to monitor my Lymphoma
- What blood tests are used to monitor Lymphoma
- Lymphoma and I am pregnant — what are my options
- Desperately seeking help and experiences for relapsed-refractory double-hit DLBCL after CAR-T. A family member has...
- Is proton therapy an option for Lymphoma
- Is surgery an option for metastatic Lymphoma
- What are the latest treatment options for lymphoma
- Looking for advice about the shot they give to boost WBC count. My husband had it last Wednesday and we are not...